TY - JOUR AU - Díaz-Vico, Tamara AU - Fernández-Martínez, Daniel AU - García-Gutiérrez, Carmen AU - Suárez-Sánchez, Aida AU - Cifrián-Canales, Isabel AU - Mendoza-Pacas, Guillermo Eduardo AU - Sánchez-Farpón, Herminio AU - Truán-Alonso, Nuria PY - 2019 TI - Mucinous adenocarcinoma arising from chronic perianal fistula—a multidisciplinary approach JF - Journal of Gastrointestinal Oncology; Vol 10, No 3 (June 01, 2019): Journal of Gastrointestinal Oncology Y2 - 2019 KW - N2 - Mucinous adenocarcinoma (MA) is a rare entity. Indeed, the pathogenesis of fistula-associated perianal MA is still controversial. Due to the lack of informed evidence regarding this malignancy, no guidelines have been established concerning diagnostic and treatment strategies. The aim of this article is to report our experience and outcomes after three cases of large perianal MA treated in our center. From our retrospective chart review, we identified three male patients with chronic perianal fistula-in-ano who progressively developed perianal MA, confirmed by pelvic magnetic resonance (MRI) and histopathological examination performed on biopsy. We hereby, in accordance with the Surgical CAse REport (SCARE) guidelines, describe the management and further follow-up of each patient. The three patients underwent preoperative chemoradiation therapy, followed by ischioanal abdominoperineal resection (APR). Perineal reconstruction was needed in every case, using a vertical rectus abdominis myocutaneous (VRAM) flap and, punctually, a left fasciocutaneous flap was used too. Also, two of three patients completed the treatment with adjuvant chemotherapy. Neither recurrences nor distant metastases have been observed during the follow-up in both cases that finished the multimodal treatment. MA arising from chronic perianal fistula has an indolent growth with locoregional aggressiveness and a high risk of local recurrence. Therefore, although an ischioanal APR remains the surgical treatment of choice, an aggressive multimodal approach combining preoperative chemoradiation and adjuvant chemotherapy may achieve favorable effectiveness and promising response rates. UR - https://jgo.amegroups.org/article/view/27102